FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

AI Optics Handheld Retinal Imager Cleared

FDA clears an AI Optics 510(k) for its Sentinel Camera, a handheld retinal imaging device for capturing images of the human eye.

latest-news-card-1

TerSera Wants Prialt ANDA Conditions

TerSera petitions FDA to require any ANDA referencing Prialt to conduct compatibility testing with the Medtronic pump that is specified in Prialts lab...

latest-news-card-1
FDA General

RFK Jr.s Cousin Trashes Him on Eve of Hearing

Robert F. Kennedy Jr.s cousin, Caroline Kennedy, sends a scathing letter about his background to U.S. senators on the eve of a confirmation hearing to...

latest-news-card-1
Human Drugs

Additional Ozempic Indication Approved

FDA approves a new indication for Novo Nordisks Ozempic to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

latest-news-card-1
Medical Devices

Alzheimers Assay Gets Breakthrough Designation

FDA grants Beckman Coulter Diagnostics a breakthrough device designation for its Access p‑Tau217/β-Amyloid 1-42 plasma ratio assay to help ...

latest-news-card-1
Medical Devices

Stroke Device Cleared for Larger Catheters

FDA clears an Imperative Care 510(k) for its Zoom System, a stroke thrombectomy system with .088-inch catheters.

Human Drugs

Supernus Wins Label Update for ADHD Drug

FDA approves a Supernus Pharmaceuticals label update for attention-deficit/hyperactivity disorder drug Qelbree (viloxazine extended-release capsules) ...

latest-news-card-1
Human Drugs

Provepharm Recalls Phenylephrine HCl

Provepharm recalls one lot of phenylephrine hydrochloride injection, USP, 10 mg/mL due to a customer complaint about visible black particulate matter ...

latest-news-card-1
Human Drugs

Once Monthly Leqembi for Alzheimers Approved

FDA approves an Eisai/Biogen supplemental BLA for Leqembi (lecanemab-irmb) and its intravenous use once every four weeks as maintenance dosing in Alzh...

latest-news-card-1
Human Drugs

Pfizer Pays $60 million to Settle Biohaven Kickbacks

Pfizer agrees to pay $59.7 million to resolve allegations that its subsidiary, Biohaven Pharmaceutical, engaged in previous illegal kickback schemes.